Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ilander, Mette ^a   Kreutzman, Anna ^a   Rohon, Peter ^b   Melo, Teresa ^c   Faber, Edgar ^b   Porkka, Kimmo ^a   Vakkila, Jukka ^a   Mustjoki, Satu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; K562 CELL LINE; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; MONOTHERAPY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; TH1 CELL; YOUNG ADULT;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; INTERFERON-ALPHA; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; TH1 CELLS;

EID: 84900418447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087794     Document Type: Article

References (42)

1. Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370: 342-350. (Pubitemid 47094995)
2. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356.
3. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061.
4. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, et al. (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270.
5. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259.
6. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K (2011) Interferon alpha for treatment of chronic myeloid leukemia. Current Drug Targets 12: 420-428.
7. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532-538.
8. Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, et al. (1992) Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79: 1920-1923.
9. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, et al. (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20: 214-220. (Pubitemid 34032614)
10. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, et al. (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98: 3074-3081.
11. Deng M, Daley GQ (2001) Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97: 3491-3497.
12. Cortes J, Fayad L, Kantarjian H, O'Brien S, Lee MS, et al. (1998) Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12: 455-462. (Pubitemid 28197567)
13. Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, et al. (1998) Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12: 155-163. (Pubitemid 28108067)
14. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, et al. (2003) Interferonalpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101: 259-264. (Pubitemid 36025916)
15. Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, et al. (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118: 3228-3235.
16. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004. (Pubitemid 36302244)
17. Wu SH, Zheng CP, Xu J (2012) [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-alpha]. Zhonghua Xue Ye Xue Za Zhi 33: 311-315.
18. Koskenvesa P KA, Rohon P, Pihlman M, Vakkila E et al. (2013) Imatinib and pegylated IFN-alpha2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. In press.
19. Burchert A, Muller MC, Kostrewa P, Erben P, Bostel T, et al. (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28: 1429-1435.
20. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, et al. (2011) Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 6: e23022.
21. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, et al. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363: 2511-2521.
22. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
23. Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, et al. (2013) Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 49: 3242-3246.
24. Ilander M, Koskenvesa P, Hernesniemi S, Lion T, Porkka K, et al. (2013) Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy. Leuk Lymphoma 0: 1-4.
25. Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, et al. (2012) Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 95: 209-213.
26. Powell DJ, Jr., Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250. (Pubitemid 40053089)
27. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: 16168-16173. (Pubitemid 35462767)
28. Deng Y, Jing Y, Campbell AE, Gravenstein S (2004) Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172: 3437-3446. (Pubitemid 38337923)
29. Usuki K, Yokoyama K, Nagamura-Inoue T, Ito A, Kida M, et al. (2009) CD8+ memory T cells predominate over naive T cells in therapy-free CML patients with sustained major molecular response. Leuk Res 33: e164-165.
30. Yan J, Greer JM, Hull R, O'Sullivan JD, Henderson RD, et al. (2010) The effect of ageing on human lymphocyte subsets: comparison of males and females. Immun Ageing 7: 4.
31. Keene JA, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155: 768-782. (Pubitemid 12187851)
32. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, et al. (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494: 361-365.
33. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186: 65-70. (Pubitemid 27304848)
34. Pawelec G, Da Silva P, Max H, Kalbacher H, Schmidt H, et al. (1995) Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma 18: 471-478.
35. de Castro FA, Palma PV, Morais FR, Simoes BP, Carvalho PV, et al. (2003) Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 44: 2061-2067. (Pubitemid 37369645)
36. Sun H, Sun C, Xiao W (2014) Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine 65: 33-41.
37. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, et al. (2010) CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 116: 1299-1307.
38. Sun JC, Beilke JN, Bezman NA, Lanier LL (2011) Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 208: 357-368.
39. Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457: 557-561.
40. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, et al. (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119: 2665-2674.
41. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, et al. (2011) Expansion of a unique CD57 (+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 108: 14725-14732.
42. Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132: 536-544.